Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines

[1]  N. Munshi,et al.  JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells* , 2003, The Journal of Biological Chemistry.

[2]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[3]  T. Hideshima,et al.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma , 2002, Nature Reviews Cancer.

[4]  Masaharu Akiyama,et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.

[5]  N. Munshi,et al.  Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. , 2002, Blood.

[6]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[7]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Chauhan,et al.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.

[9]  P. Richardson,et al.  The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications , 2001, Oncogene.

[10]  M. Karin,et al.  c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. , 2001, The Journal of clinical investigation.

[11]  M. Lai,et al.  c-Jun NH2-terminal Kinase Activation Leads to a FADD-dependent but Fas Ligand-independent Cell Death in Jurkat T Cells* , 2001, The Journal of Biological Chemistry.

[12]  Zhi-Min Yuan,et al.  Translocation of SAPK/JNK to Mitochondria and Interaction with Bcl-xL in Response to DNA Damage* , 2000, The Journal of Biological Chemistry.

[13]  I. Herr,et al.  JNK/SAPK activity contributes to TRAIL-induced apoptosis , 1999, Cell Death and Differentiation.

[14]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[15]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[16]  K. Anderson,et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.

[17]  Martin S. Fridson,et al.  Trends , 1948, Bankmagazin.